Multisystem Processes & Disorders

Skin and soft tissue MRSA: outpatient management

Clinical Overview and When to Suspect MRSA SSTI

— Predominant US strain: USA300 (SCCmec type IV, PVL toxin-producing), causing aggressive abscesses, furunculosis, and necrotizing fasciitis.

— Distinct from healthcare-associated MRSA (HA-MRSA), which more often causes bacteremia, pneumonia, and surgical site infection.

— Any purulent lesion: abscess, furuncle, carbuncle, or cellulitis with drainage.

— Lesions described as "spider bite" by the patient — classic CA-MRSA stem.

— Recurrent boils, multiple family members affected, or close-contact clusters.

— Risk environments: jails/prisons, military barracks, contact sports (wrestling, football), gyms, daycares, MSM communities, IV drug use, homeless shelters.

— Failure of beta-lactam (cephalexin, dicloxacillin) monotherapy after 48–72 hours.

— ~30% of the US population is colonized with S. aureus; ~1–2% with MRSA, often in anterior nares, axilla, groin, perineum.

— Colonization precedes infection — and drives household recurrence.

Community-acquired MRSA (CA-MRSA) is now the dominant cause of purulent skin and soft tissue infection (SSTI) in US outpatient and ED settings, eclipsing methicillin-susceptible S. aureus in many regions.

When to suspect MRSA in an outpatient SSTI:

Non-purulent cellulitis (no drainage, no abscess, no penetrating trauma) is typically streptococcal — MRSA coverage not routinely required unless systemic toxicity or failure of beta-lactam therapy.

Epidemiology pearls:

Step 3 management: In the ambulatory setting, the decision tree pivots on purulent vs non-purulent and mild vs moderate vs severe. Purulent + drainable = I&D first, antibiotics second. This single decision drives most outpatient MRSA SSTI questions.

Board pearl: A patient with a fluctuant lesion who says "I think a spider bit me" — assume CA-MRSA until proven otherwise, especially with athletic, correctional, or household-cluster context.

Presentation Patterns and Key History

— Furuncle (boil): deep folliculitis with a single pustule, often on buttocks, thighs, axillae, neck.

— Carbuncle: coalescing furuncles draining through multiple sinus tracts; usually posterior neck, back.

— Abscess: fluctuant, tender, erythematous nodule with central pointing or spontaneous drainage.

— Purulent cellulitis: diffuse erythema with associated abscess or drainage.

— Duration and progression — rapid expansion (hours) suggests necrotizing process; days suggests typical SSTI.

— Trauma, IVDU, tattoo, shaving, depilation — portals of entry.

— Prior MRSA infection or colonization — single best predictor of recurrence.

— Household contacts with similar lesions — drives decolonization planning.

— Recent antibiotics or hospitalization within 90 days — shifts toward HA-MRSA resistance patterns.

— Athletic/occupational exposures: wrestling mats, shared towels, locker rooms, correctional facilities, military housing.

— Comorbidities: diabetes, HIV, eczema, lymphedema, peripheral vascular disease, chronic kidney disease.

— Systemic symptoms: fever, chills, rigors, malaise — flags for moderate/severe disease.

— Pain out of proportion to exam → necrotizing fasciitis.

— Crepitus, dusky skin, bullae, anesthesia over lesion.

— Rapid expansion of erythema marked at the border.

— Immunocompromise (chemotherapy, neutropenia, transplant).

Classic purulent presentations:

History elements to elicit (high-yield on CCS-style stems):

Red-flag history prompting urgent escalation:

Key distinction: Recurrent SSTI (≥2 episodes at distinct sites within 6 months) shifts management beyond the acute episode toward decolonization (intranasal mupirocin, chlorhexidine body washes, household hygiene measures) — a favorite Step 3 longitudinal-care question.

Board pearl: A wrestler with a tender thigh nodule and a teammate "with the same thing last week" is CA-MRSA; ask about shared razors, towels, and equipment — these drive both treatment and prevention counseling.

Physical Exam Findings and Severity Assessment

— Erythema, warmth, swelling, induration; mark the leading edge with a skin marker and date/time it — standard of care for tracking progression.

— Fluctuance on palpation = collectible pus = I&D indicated.

— Central pointing or spontaneous drainage of yellow-white purulent material.

— Satellite pustules, surrounding folliculitis.

— Mild: purulent SSTI without systemic signs of infection. → I&D alone often sufficient.

— Moderate: purulent SSTI with systemic signs (T >38°C, HR >90, RR >24, WBC >12k or <4k) OR immunocompromise. → I&D + oral antibiotics.

— Severe: failed I&D + oral abx, OR SIRS with hypotension, OR signs of deeper infection (necrotizing, organ dysfunction). → IV antibiotics, surgical consultation, hospitalization.

— Vital signs at every visit; SIRS criteria define moderate-to-severe disease.

— Hypotension, tachycardia, altered mentation, or lactate elevation → sepsis pathway, transfer to ED.

— Lymphangitic streaking and regional lymphadenopathy — concerning but not necessarily severe.

— Pain disproportionate to visible findings.

— Skin: dusky discoloration, hemorrhagic bullae, anesthesia, crepitus.

— Rapid border expansion despite antibiotics.

— Step 3 management: any of these → immediate surgical consultation and hospital transfer; do not delay for imaging.

— Facial lesions near nasolabial triangle → risk of cavernous sinus thrombosis; lower threshold for IV therapy.

— Hand/perineal/joint-overlying lesions → consider surgical consultation.

— Diabetic foot lesions → assess for osteomyelitis (probe-to-bone test).

Inspection:

Severity classification (IDSA framework — memorize for Step 3):

Hemodynamic and systemic assessment:

Necrotizing fasciitis red flags on exam:

Special anatomic considerations:

CCS pearl: Document lesion size, presence of fluctuance, border demarcation, and vital signs at initial visit; re-examination at 48–72 hours is the standard outpatient interval — order "Return visit in 2 days" or telehealth check.

Diagnostic Workup — Initial Evaluation

— Obtain from purulent material at the time of I&D in essentially all cases — guides therapy if patient fails empiric treatment and tracks local antibiogram.

— Swab the base of the abscess cavity after evacuation, not the overlying skin.

— Gram stain: gram-positive cocci in clusters.

— Culture turnaround 24–72 hours; susceptibilities including clindamycin D-test (for inducible resistance) are key.

— CBC with differential, BMP, lactate if SIRS.

— Glucose/HbA1c in suspected new or poorly controlled diabetes.

— CRP useful for trending in moderate cases; not diagnostic alone.

— Bedside ultrasound is the imaging modality of choice when fluctuance is equivocal — distinguishes cellulitis from drainable abscess, often changes management.

— CT or MRI if deep/necrotizing infection suspected, but never delay surgical consultation for imaging in necrotizing fasciitis.

— Plain films if foreign body, gas in tissues, or osteomyelitis suspected.

— Not for acute diagnosis.

— Useful in recurrent SSTI workup and preoperative decolonization protocols.

Most outpatient purulent SSTIs are a clinical diagnosis — extensive labs/imaging are not routinely needed for mild disease.

Wound culture and Gram stain:

Blood cultures: indicated for moderate-to-severe SSTI, systemic toxicity, immunocompromise, or extensive disease — not routine for simple outpatient abscess.

Basic labs (when systemic signs present):

Imaging:

Nasal screening swabs for MRSA colonization:

LRINEC score (Lab Risk Indicator for Necrotizing Fasciitis): CRP, WBC, Hb, Na, Cr, glucose; ≥6 raises suspicion, ≥8 strongly suggests necrotizing infection — but clinical judgment trumps the score.

Board pearl: Always culture pus at the time of I&D — exam questions reward this even when empiric therapy is started immediately, because it documents local resistance and supports therapy adjustment if the patient returns.

Key distinction: Surface skin swabs of intact cellulitis are low-yield and not recommended; culture only drainable material or aspirate.

Diagnostic Workup — Confirmatory and Advanced Studies

— Oxacillin/cefoxitin resistant = MRSA confirmed.

— Clindamycin susceptible + erythromycin resistant → request D-test to detect inducible clindamycin resistance (MLSB phenotype). Positive D-test = treat as clindamycin-resistant.

— TMP-SMX, doxycycline, linezolid, vancomycin susceptibilities reported routinely.

— PCR for mecA gene or rapid MRSA assays available in some EDs/hospitals; useful for rapid de-escalation or escalation of empiric therapy.

— PVL gene testing exists but is epidemiologic, not used in routine clinical decisions.

— MRI is the gold standard for suspected osteomyelitis, pyomyositis, or necrotizing fasciitis (in stable patients).

— CT with contrast for retroperitoneal, perirectal, or deep neck space infections.

— Ultrasound for ongoing abscess monitoring and drainage adequacy.

— Obtain if bacteremia, persistent fever, new murmur, or IV drug use — S. aureus bacteremia mandates evaluation for endocarditis.

— Consider in recurrent or unusually severe SSTI — Step 3 favors USPSTF universal screening (ages 15–65) regardless.

— Fasting glucose or HbA1c in patients with first-time SSTI without known DM, especially with carbuncles or recurrent furunculosis.

— Nares, axilla, groin, perineum swabs.

— Consider household member screening if clusters identified.

Susceptibility testing — what to actually look at on the report:

Molecular diagnostics:

Imaging in select cases:

Echocardiogram (TTE/TEE):

HIV testing:

Diabetes screening:

Colonization workup for recurrent disease (≥2 episodes/6 months):

Step 3 management: A patient returning with a second abscess in 4 months triggers a longitudinal workup — culture, susceptibility, HbA1c, HIV (if not done), and decolonization protocol (intranasal mupirocin BID × 5 days + chlorhexidine 4% daily washes × 5–14 days) plus hygiene counseling.

Board pearl: Inducible clindamycin resistance (D-test positive) is a classic distractor — clindamycin "looks susceptible" on initial report but fails clinically.

Risk Stratification and Management Algorithm

— No (non-purulent cellulitis, no abscess, no drainage): treat empirically for β-hemolytic streptococci with cephalexin or dicloxacillin; MRSA coverage only if systemic toxicity, prior MRSA, or failure of β-lactam.

— Yes: proceed to Step 2.

— Fluctuant or ≥2 cm abscess: incision and drainage (I&D) is the cornerstone of management.

— Small (<2 cm) furuncle: warm compresses may suffice in mild cases.

— Mild (no systemic signs, immunocompetent, abscess <2 cm): I&D alone is often curative; however, current IDSA-supported evidence favors adjunct TMP-SMX or clindamycin to reduce treatment failure and recurrence, especially for lesions ≥2 cm.

— Moderate (systemic signs, multiple sites, immunocompromise, comorbidities, failure of I&D alone, lesions on face/hands/genitalia): I&D + oral MRSA-active antibiotics × 5–7 days.

— Severe (SIRS/sepsis, deep/necrotizing infection, failed outpatient therapy): hospitalize, IV vancomycin or alternative, surgical consultation.

— TMP-SMX 1–2 DS tablets BID.

— Doxycycline 100 mg BID.

— Clindamycin 300–450 mg QID (consider D-test).

— Linezolid (expensive, reserved).

The decision tree (memorize cold):

Step 1 — Is it purulent?

Step 2 — Drainable?

Step 3 — Severity stratification (post-I&D):

Empiric oral MRSA-active agents (outpatient):

Duration: 5–7 days typical; extend to 7–14 days if slow response or complicated.

Step 3 management: Schedule 48–72 hour reassessment in person or by telehealth. If erythema/induration unchanged or worse, broaden coverage, image for undrained collection, or escalate to IV/inpatient.

Board pearl: I&D alone may suffice for small, simple abscesses — but adding TMP-SMX × 7 days reduces treatment failure and new lesion formation (landmark NEJM data); current Step 3 answers favor I&D + antibiotic for most patients with abscess ≥2 cm.

Key distinction: Non-purulent cellulitis = strep; purulent SSTI = think MRSA.

Pharmacotherapy — First-Line Outpatient Regimens

— Dose: 1–2 DS (160/800 mg) tablets PO BID × 5–7 days.

— Pros: excellent MRSA activity, low resistance, cheap, well-studied.

— Cons: sulfa allergy, hyperkalemia, AKI, photosensitivity, ↑INR with warfarin, ↑methotrexate toxicity, neonatal kernicterus (avoid late pregnancy).

— Does not cover group A strep reliably — if mixed cellulitis/abscess picture and strep coverage also needed, combine with cephalexin or use clindamycin alone.

— Dose: 100 mg PO BID × 5–7 days.

— Pros: covers MRSA and most strep adequately for SSTI; useful in sulfa allergy.

— Cons: avoid in pregnancy and children <8 (tooth staining, though short courses now considered acceptable in some pediatric guidelines), photosensitivity, esophagitis (take upright with water).

— Dose: 300–450 mg PO QID × 5–7 days.

— Pros: covers MRSA, strep, and suppresses toxin production (useful in necrotizing/toxin-mediated disease).

— Cons: inducible resistance (D-test required), C. difficile (highest risk class), GI intolerance, QID dosing limits adherence.

— Dose: 600 mg PO BID × 7–14 days.

— Cons: cost, thrombocytopenia with prolonged use, serotonin syndrome with SSRIs/MAOIs, peripheral/optic neuropathy.

— Cephalexin 500 mg QID + TMP-SMX DS BID.

— Cephalexin, dicloxacillin, amoxicillin-clavulanate alone (no MRSA activity).

— Fluoroquinolones (high resistance, adverse effect profile).

— Macrolides (resistance, drug interactions).

TMP-SMX (trimethoprim-sulfamethoxazole) — preferred first-line for outpatient MRSA SSTI.

Doxycycline — strong alternative.

Clindamycin — historic mainstay, decreasing utility.

Linezolid — reserved, expensive.

Combination therapy — for purulent cellulitis where both strep and MRSA need coverage and clinician prefers β-lactam:

Avoid for MRSA SSTI:

Step 3 management: Document allergy history before prescribing; counsel on photoprotection (TMP-SMX, doxycycline), drug interactions (warfarin + TMP-SMX, SSRIs + linezolid), and completion of full course even after symptom resolution.

Board pearl: TMP-SMX + cephalexin is the classic stem answer for the patient with purulent cellulitis where you want both MRSA and strep coverage but the question stem hints at need for β-lactam reliability.

Procedures — Incision and Drainage Technique and Care

— Fluctuant abscess (clinical or ultrasound-confirmed).

— Furuncle/carbuncle with pus.

— Failed conservative management of small lesions.

— Informed consent: bleeding, infection, scarring, recurrence.

— Local anesthesia: 1% lidocaine with epinephrine (avoid epinephrine in digits, nose, ears, penis — older teaching, though increasingly questioned).

— Consider regional/field block for sensitive areas.

— Topical EMLA in pediatric patients.

— Linear incision along skin tension lines, through the most fluctuant point.

— Adequate length to allow drainage and exploration.

— Break up loculations with hemostat or gloved finger.

— Express purulent material; culture the cavity base.

— Irrigate with saline (benefit modest; not mandatory).

— Loop drainage technique (vessel loop through two stab incisions) — increasingly preferred, less painful packing, comparable outcomes.

— Traditional packing with iodoform or plain gauze acceptable, though evidence for routine packing of small abscesses is weak — may not be necessary for <5 cm cavities.

— Cover with dry sterile dressing.

— Pain control: acetaminophen, NSAIDs; opioids rarely needed.

— Wound care instructions: keep clean, change dressing daily, hand hygiene before/after.

— Follow-up at 48–72 hours for reassessment, packing change/removal.

— Hand, face (nasolabial triangle), perirectal, breast (consider deeper involvement), genital abscesses.

— Deep neck space infections.

— Suspected pilonidal disease, hidradenitis suppurativa requiring definitive surgery.

— Suspected necrotizing fasciitis → emergent surgical debridement.

I&D is the single most important intervention for cutaneous MRSA abscess. Antibiotics without drainage frequently fail.

Indications:

Pre-procedure:

Technique:

Post-procedure:

When to refer for surgical management:

CCS pearl: Order "Incision and drainage, wound culture, Gram stain" as bundled actions; then "Return visit in 48–72 hours" and a prescription for TMP-SMX DS BID × 7 days to complete the simulated outpatient encounter cleanly.

Board pearl: Adequate I&D + culture + 48-hr follow-up is the canonical Step 3 answer for the fluctuant purulent lesion — questions reward proceduralism over "empiric antibiotics alone."

Special Populations — Elderly, Renal, and Hepatic Impairment

— Higher rates of comorbidities (DM, CKD, peripheral vascular disease, immunosenescence) → lower threshold for systemic antibiotics and closer follow-up.

— Atypical presentations: minimal fever, more confusion, falls.

— Polypharmacy risks: TMP-SMX interactions with warfarin (↑INR), ACE inhibitors/ARBs (↑K⁺), sulfonylureas (↑hypoglycemia), spironolactone (severe hyperkalemia).

— Skin fragility complicates dressings and adherence.

— TMP-SMX: reduce dose if CrCl <30 mL/min; monitor potassium and creatinine. Avoid if CrCl <15 unless on dialysis with adjustment.

— Doxycycline: no renal dose adjustment — preferred in CKD/ESRD.

— Clindamycin: no renal adjustment — also a safe choice.

— Vancomycin (if escalated to IV): trough or AUC-based dosing; AKI risk especially with concurrent nephrotoxins.

— Doxycycline: caution in severe liver disease.

— Clindamycin: hepatically cleared; use with caution and monitor LFTs in severe dysfunction.

— TMP-SMX: rare hepatotoxicity; generally usable with monitoring.

— Linezolid: caution; can worsen thrombocytopenia in cirrhosis.

— Aggressively manage glycemic control during infection.

— Lower threshold to image for osteomyelitis in foot lesions (probe-to-bone, plain film, MRI).

— Consider podiatry and wound care referral.

— TMP-SMX significantly potentiates warfarin → INR rise within days; either avoid (use doxycycline or clindamycin) or monitor INR at days 3–5 and adjust.

— TMP-SMX increases methotrexate toxicity (pancytopenia) — avoid.

Elderly patients:

Renal impairment:

Hepatic impairment:

Diabetics:

Patients on warfarin:

Patients on methotrexate:

Step 3 management: In an 82-year-old on warfarin and lisinopril with a forearm abscess, prefer I&D + doxycycline 100 mg BID × 7 days rather than TMP-SMX — sidesteps INR and hyperkalemia disasters.

Board pearl: Doxycycline and clindamycin require no renal dose adjustment — high-yield for CKD/ESRD stems.

Special Populations — Pregnancy, Pediatrics, and Athletes

— Cephalexin and dicloxacillin safe but don't cover MRSA.

— Clindamycin: first-line MRSA-active oral agent in pregnancy — Category B-equivalent, broadly safe.

— TMP-SMX: avoid in first trimester (neural tube defects — folate antagonism) and near term (kernicterus, hyperbilirubinemia). Use only if alternatives unsuitable in mid-pregnancy.

— Doxycycline: contraindicated (fetal tooth/bone effects).

— Vancomycin IV: acceptable for severe disease.

— Coordinate with obstetrics; check on GBS status and prevent transmission.

— Clindamycin, cephalexin compatible.

— TMP-SMX acceptable for healthy term infants >2 months; avoid in premature/jaundiced/G6PD-deficient newborns.

— Doxycycline: short courses (≤21 days) now considered acceptable per AAP, though clindamycin/TMP-SMX preferred.

— Clindamycin 10–13 mg/kg/dose PO TID or TMP-SMX 8–12 mg/kg/day of TMP divided BID are first-line.

— Doxycycline historically avoided <8 years for cosmetic tooth staining; AAP now permits short courses (≤21 days) at any age — useful when other options limited (e.g., RMSF, MRSA in TMP-SMX intolerance).

— Weight-based dosing; check pediatric formulary.

— Consider child abuse evaluation if recurrent lesions in suspicious distribution or poor hygiene context.

— Mandatory exclusion from contact play until lesions dry, well-covered, or healed per NCAA/NFHS rules (typically ≥72 hours of antibiotic therapy AND no drainage AND lesion covered).

— Counsel: no shared towels, razors, or equipment; shower after practice; launder gear in hot water; mat disinfection.

— High MRSA SSTI burden; screen for HIV, HCV, HBV; consider endocarditis if febrile.

— Linkage to substance use disorder treatment, harm reduction, naloxone.

Pregnancy:

Breastfeeding:

Pediatrics:

Athletes (wrestlers, football, MMA):

IV drug users:

Board pearl: Clindamycin = pregnancy-safe MRSA oral agent; doxycycline is contraindicated in pregnancy; TMP-SMX is unsafe in 1st trimester and near term.

Step 3 management: Always document return-to-play criteria for athlete stems and household contact counseling for pediatric recurrent abscess.

Complications and Adverse Outcomes

— Recurrence at the same or new sites (15–40% in CA-MRSA cohorts).

— Cellulitis spread from inadequately drained abscess.

— Lymphangitis, lymphadenitis.

— Scarring, chronic sinus tracts, hidradenitis-like changes in recurrent disease.

— Pyomyositis — S. aureus most common; MRSA increasingly implicated. Presents with deep muscle pain, fever, tenderness; MRI diagnostic.

— Septic arthritis — joint-overlying SSTI penetrating into joint space.

— Osteomyelitis — especially in diabetic foot, IVDU, or contiguous spread.

— Necrotizing fasciitis — surgical emergency.

— Bacteremia — S. aureus bacteremia mandates TTE/TEE, repeat blood cultures every 48–72 hours until clearance, 2-week minimum IV therapy, source control.

— Endocarditis — particularly in IVDU; right-sided tricuspid involvement classic.

— Septic pulmonary emboli — bilateral cavitary nodules on CT.

— Sepsis/septic shock.

— Toxic shock syndrome — PVL/TSST-1 toxin–mediated; fever, rash, hypotension, multiorgan dysfunction.

— TMP-SMX: hyperkalemia, AKI, SJS/TEN, hyponatremia, hypoglycemia, hematologic toxicity.

— Clindamycin: C. difficile colitis — highest-risk antibiotic class.

— Doxycycline: photosensitivity, esophagitis, GI upset.

— Vancomycin: AKI, infusion reaction (red man), ototoxicity.

— Linezolid: thrombocytopenia, serotonin syndrome, optic/peripheral neuropathy.

— Bleeding (consider on anticoagulation), nerve injury (facial, digital), inadequate drainage.

— Transmission to family members, athletic teams, correctional populations.

Local complications:

Deep tissue extension:

Systemic complications:

Treatment-related adverse events:

Procedural complications:

Public health/household:

Key distinction: Necrotizing fasciitis vs severe cellulitis — pain disproportionate to exam, hemorrhagic bullae, crepitus, anesthesia, rapidly advancing border, elevated LRINEC → OR for debridement, not more antibiotics.

Board pearl: S. aureus bacteremia is never "just" bacteremia — always image/echo for endocarditis and ensure source control; minimum 14 days of IV therapy for uncomplicated, 4–6 weeks for complicated.

Escalation — When to Send to ED or Admit

— Hemodynamic instability: hypotension, tachycardia, hypoxia, altered mentation.

— SIRS/sepsis criteria with SSTI source.

— Suspected necrotizing fasciitis (any red flag).

— Suspected deep space infection (perirectal, deep neck, retroperitoneal).

— Bacteremia or extension into joint/bone.

— Failure of outpatient oral therapy after 48–72 hours despite adequate I&D.

— Inability to tolerate POs or unreliable adherence.

— Immunocompromise: neutropenia, transplant, advanced HIV.

— Extensive cellulitis with rapidly advancing border.

— Surgery: necrotizing infection, hand/face/perineal abscess, recurrent complex abscess, suspected deep extension.

— Infectious disease: persistent bacteremia, multidrug-resistant organisms, recurrent infections, treatment failure, immunocompromise.

— Dermatology: chronic recurrent furunculosis, hidradenitis suppurativa differential.

— Plastic surgery: cosmetically sensitive areas, complex closure.

— Vancomycin IV (weight-based, trough 15–20 or AUC 400–600).

— Daptomycin 4–6 mg/kg IV daily (do not use for pneumonia — inactivated by surfactant).

— Linezolid 600 mg IV/PO q12h.

— Ceftaroline — 5th-gen cephalosporin with MRSA activity.

— Clindamycin IV — adjunct for toxin-mediated disease (TSS, nec fasc).

— Vancomycin + piperacillin-tazobactam + clindamycin (clindamycin for toxin suppression) — plus emergent surgical debridement.

Immediate ED transfer / hospital admission criteria:

Specialist consultation:

IV antibiotic options (inpatient):

Necrotizing fasciitis empiric regimen:

CCS pearl: In a simulated case, if vitals show T 39, HR 118, BP 92/58, lactate 3.2 in a patient with extensive thigh erythema, your CCS sequence is: 2 large-bore IVs → crystalloid bolus → blood cultures ×2 → vancomycin + piperacillin-tazobactam + clindamycin → surgical consult STAT → admit ICU. Imaging follows, but does not delay surgery.

Step 3 management: Discharge planning starts at admission — anticipate 2 weeks of IV access for bacteremia, arrange OPAT (outpatient parenteral antibiotic therapy) if appropriate, schedule ID follow-up within 1 week.

Key Differentials — Other Bacterial SSTIs

— Same clinical phenotype as MRSA; differentiated only by susceptibility testing.

— Once susceptibilities return, narrow to cefazolin (IV) or cephalexin/dicloxacillin (PO) — β-lactams outperform vancomycin against MSSA.

— Classic cause of non-purulent cellulitis and erysipelas (sharply demarcated, raised, "orange peel" border, often facial).

— Treat with cephalexin, dicloxacillin, penicillin, or amoxicillin.

— Can also cause necrotizing fasciitis (type II — monomicrobial).

— Mixed aerobes/anaerobes — diabetic, immunocompromised, post-surgical patients.

Methicillin-susceptible S. aureus (MSSA):

Group A Streptococcus (GAS, S. pyogenes):

Group B Streptococcus: Cellulitis in diabetics, postpartum, neonates.

Polymicrobial (type I) necrotizing fasciitis:

Pasteurella multocida: Animal bites (cat > dog) — rapid-onset cellulitis within 24 hours. Treat with amoxicillin-clavulanate.

Eikenella corrodens: Human bites (clenched-fist injury). Treat with amoxicillin-clavulanate; consider hand surgery referral.

Vibrio vulnificus: Saltwater exposure, raw oysters; hemorrhagic bullae, rapid progression in cirrhotics/iron overload. Treat with doxycycline + ceftriaxone.

Aeromonas hydrophila: Freshwater exposure, leech use; treat with fluoroquinolone or TMP-SMX + doxycycline.

Erysipelothrix rhusiopathiae: Fish handlers, butchers — purplish hand lesion.

Mycobacterium marinum: Aquarium/fish tank — chronic nodular lymphangitis.

Pseudomonas aeruginosa: Hot tub folliculitis, ecthyma gangrenosum in neutropenic patients, malignant otitis externa, diabetic foot.

Anaerobes (Clostridium perfringens): Gas gangrene — crepitus, bronze skin, traumatic wound.

Key distinction: Purulent SSTI → MRSA/MSSA; non-purulent SSTI → strep. Animal bite → Pasteurella + skin flora → amox-clav. Saltwater + cirrhosis → Vibrio.

Board pearl: Sharply demarcated, fiery red, raised facial lesion with fever = erysipelas = GAS — treat with penicillin or cephalexin, not MRSA coverage.

Key Differentials — Non-Infectious and Mimics

— Bilateral, lower-extremity, chronic, hyperpigmented, weeping; lacks systemic signs.

— Misdiagnosed as cellulitis ~30% of the time.

— Treat with compression, elevation, topical steroids — not antibiotics.

— Unilateral leg swelling, pain — may mimic cellulitis. Obtain D-dimer/ultrasound when erythema is minimal but swelling/pain prominent.

— Recurrent erysipelas/cellulitis in lymphedematous limb; prophylactic penicillin may be considered.

— Pruritus rather than pain; well-demarcated to exposure area; vesicles.

— Expanding annular erythema with central clearing; tick exposure; treat with doxycycline.

— Monoarticular joint with erythema, warmth, severe pain — easily mistaken for SSTI overlying joint; check uric acid, joint aspiration.

— Drug history critical; mucosal involvement → think SJS/TEN.

— Painful ulcer with violaceous undermined border; associated with IBD, RA; worsens with debridement (pathergy) — biopsy and immunosuppression, not surgery.

— Recurrent nodules/abscesses in axillae, groin, perineum, inframammary; sinus tracts; chronic course.

— Treatment: weight loss, smoking cessation, topical clindamycin, oral antibiotics, biologics (adalimumab).

— Tender erythematous plaques, fever, neutrophilia; often paraneoplastic.

— ESRD patients; painful retiform purpura progressing to necrosis.

Cellulitis mimics ("pseudocellulitis"):

Venous stasis dermatitis:

Deep vein thrombosis (DVT):

Lymphedema and cellulitis cycle:

Contact dermatitis:

Erythema migrans (Lyme):

Gout/pseudogout:

Drug reaction (DRESS, fixed drug eruption, SJS/TEN):

Pyoderma gangrenosum:

Hidradenitis suppurativa:

Sweet syndrome:

Calciphylaxis:

Key distinction: Bilateral lower-extremity "cellulitis" is almost never infectious cellulitis — think stasis dermatitis. Recurrent axillary/groin "abscesses" → hidradenitis suppurativa, not just MRSA.

Board pearl: A patient with chronic, recurrent axillary abscesses, sinus tracts, and scarring needs dermatology referral and HS workup — not endless antibiotic courses.

Secondary Prevention and Decolonization

— Recurrent SSTI (≥2 episodes in 6 months).

— Household clusters or transmission within close-contact groups.

— Patient/family request after first severe episode in high-risk setting (athletes, military).

— Pre-operative MRSA carriers (cardiac, orthopedic surgery — separate institutional protocols).

— Intranasal mupirocin 2% ointment, apply to both nares BID × 5 days.

— Chlorhexidine 4% body wash daily × 5–14 days (or dilute bleach baths: ¼ cup household bleach in full tub, 2–3×/week × several months).

— Optionally chlorhexidine mouth rinse.

— Cover draining wounds with clean, dry dressings.

— Hand hygiene with soap and water or alcohol-based sanitizer.

— Do not share towels, razors, athletic equipment, bar soap, washcloths.

— Launder clothing/bedding/towels in hot water and dry on high heat.

— Clean high-touch surfaces (doorknobs, phones, gym equipment) with EPA-registered disinfectant.

— Consider simultaneous decolonization of household contacts when clusters occur — improves recurrence rates.

— Athletic facilities: disinfect mats, weights, locker rooms.

— Correctional and military settings: institutional infection control protocols.

— Optimize comorbidities: glycemic control (HbA1c <7%), eczema control, treat tinea pedis (entry portal in lower-extremity cellulitis).

— Address substance use disorder in IVDU patients — refer for MAT (buprenorphine, methadone).

— Encourage smoking cessation (impairs wound healing).

— Skin moisturization to reduce fissuring.

Indications for decolonization:

Decolonization regimen (5-day course, may repeat):

Hygiene measures (counsel all patients with MRSA SSTI):

Household decolonization:

Environmental:

Long-term plan elements:

Vaccinations review: Tdap status if traumatic wound; influenza/COVID/pneumococcal status updated as part of preventive care visits.

Step 3 management: When a patient returns for the second documented MRSA abscess in 4 months, write orders for: nasal swab cultures, mupirocin BID × 5 days + chlorhexidine washes × 14 days, household contact counseling, HbA1c, HIV screen if not done, dermatology referral if hidradenitis suspected.

Board pearl: No vaccine exists for S. aureus — decolonization + hygiene are the only proven secondary prevention strategies.

Follow-Up, Monitoring, and Counseling

— In-person or via telehealth if reliable photo documentation possible.

— Assess: pain trajectory, erythema border (compare to marked outline), drainage character, systemic symptoms, medication adherence/tolerance.

— If improving: continue current plan, complete antibiotic course.

— If unchanged or worsening: re-image (US), consider undrained collection, broaden coverage, hospitalize if systemic signs.

— Confirm resolution; remove packing if still in place.

— Review culture results — adjust antibiotics if needed.

— Address decolonization if recurrent.

— At 3 and 6 months for recurrence screening in patients with prior MRSA SSTI.

— Annual preventive visits — reinforce hygiene, address comorbidities.

— Wound care technique demonstration.

— Hand hygiene before/after dressing changes.

— Signs to return immediately: expanding redness, fever, severe pain, red streaks, drainage smell change, systemic illness.

— Antibiotic completion and side-effect monitoring.

— Photoprotection (TMP-SMX, doxycycline).

— No sharing of personal items; launder hot.

— Athletes: return-to-play criteria.

— TMP-SMX: BMP at day 5–7 if elderly, CKD, or on ACEi/ARB (potassium, creatinine).

— Clindamycin: watch for diarrhea; stop and test for C. difficile if develops.

— Linezolid (extended courses): weekly CBC, neurologic exam.

— Warfarin + TMP-SMX: INR at day 3–5.

— Antibiotic stewardship: shortest effective duration, narrow once cultures return, document indication.

— Avoid unnecessary IV when oral suffices.

48–72 hour reassessment after I&D — the cornerstone outpatient follow-up interval.

End-of-treatment visit (~day 7–10):

Long-term follow-up:

Patient counseling checklist:

Monitoring labs:

Quality and value measures:

CCS pearl: Routine CCS orders post-I&D: "Wound care instructions, TMP-SMX DS BID × 7 days, return in 48 hours, advise to return immediately if fever or worsening." This sequence closes most outpatient MRSA SSTI cases.

Board pearl: Failure to follow up at 48–72 hours is a common malpractice pitfall — Step 3 expects you to schedule it explicitly and to recognize when it's missed.

Ethical, Legal, and Patient Safety Considerations

— Document discussion of bleeding, infection, scarring, recurrence, and alternatives (warm compresses for small lesions).

— Pediatric patients: parental consent + age-appropriate assent; emancipated minors handle their own consent.

— Language-concordant care or qualified medical interpreter (not family members for sensitive details).

— ED-to-PCP: ensure 48–72 hour follow-up appointment is scheduled before discharge, not just recommended.

— Inpatient-to-outpatient: medication reconciliation (esp. warfarin, ACEi, sulfonylureas with TMP-SMX), pending culture results communicated, follow-up labs ordered.

— Pending culture results must be tracked — system failure to act on a resistant organism reported after discharge is a classic safety event and malpractice trigger.

— Avoid unnecessary MRSA coverage for non-purulent cellulitis (overuse fuels resistance and C. difficile).

— Shortest effective duration; narrow per culture.

— MRSA SSTI is not routinely reportable in most states, but clusters/outbreaks (athletic teams, correctional facilities, daycares, hospitals) trigger public health notification per state law.

— Healthcare-associated MRSA bacteremia is a CMS-reportable hospital quality measure (NHSN).

— Healthcare workers with MRSA SSTI: cover lesions, follow institutional return-to-work policy; usually no exclusion if covered and well.

— Food handlers with draining lesions: restrict food-handling per local health department.

— Athletes: NCAA/NFHS exclusion rules.

— TMP-SMX, doxycycline, and clindamycin are inexpensive and on most formularies — cost is rarely a barrier, but housing insecurity, lack of running water, and shared sleeping arrangements impair recurrence prevention. Connect to social work.

— Recurrent abscesses with neglect indicators may warrant child protective services consultation — mandated reporter obligations apply.

Informed consent for I&D:

Transitions of care — high-risk handoff points:

Antibiotic stewardship:

Public health and reporting:

Occupational exposures:

Equity and access:

Pediatric red flags:

Step 3 management: When discharging a febrile diabetic with an abscess on TMP-SMX + warfarin, the safety-critical orders are: INR check in 3–5 days, hold sulfonylurea or monitor glucose, BMP for potassium, scheduled 48-hr recheck. Missing any of these is a documented harm pathway on USMLE-style stems.

Board pearl: Closing the loop on pending culture results after discharge is the single most asked patient-safety theme around outpatient SSTI.

High-Yield Associations and Rapid-Fire Facts

CA-MRSA strain: USA300, SCCmec IV, PVL toxin → aggressive abscesses.

"Spider bite" history = CA-MRSA until proven otherwise.

Purulent SSTI → MRSA coverage; non-purulent cellulitis → strep coverage.

I&D is the cornerstone; antibiotics are adjunctive for abscess.

First-line outpatient orals: TMP-SMX, doxycycline, clindamycin.

Avoid in pregnancy: doxycycline (always), TMP-SMX (1st trimester, near term).

Pregnancy-safe MRSA oral: clindamycin.

Inducible clindamycin resistance: D-test on erythromycin-resistant, clindamycin-susceptible isolates.

TMP-SMX + warfarin → ↑INR; TMP-SMX + ACEi/ARB → hyperkalemia; TMP-SMX + methotrexate → pancytopenia.

Clindamycin = highest C. diff risk.

Doxycycline & clindamycin: no renal dose adjustment.

Decolonization: mupirocin nares BID × 5 days + chlorhexidine washes.

Recurrent SSTI: ≥2 episodes/6 months → decolonization workup.

Athletes: no shared towels/razors; return-to-play when lesions covered, dry, ≥72 hr abx, no drainage.

IVDU: screen HIV/HCV/HBV; consider endocarditis if bacteremic.

Pasteurella (cat/dog bite) → amox-clav.

Eikenella (human bite/clenched fist) → amox-clav.

Vibrio vulnificus (saltwater, cirrhosis) → doxycycline + ceftriaxone.

Necrotizing fasciitis empiric: vancomycin + pip-tazo + clindamycin + emergent debridement.

Pyoderma gangrenosum worsens with debridement (pathergy) — don't cut.

Bilateral lower-extremity "cellulitis" = stasis dermatitis until proven otherwise.

Erysipelas (sharp border, face) = GAS — penicillin/cephalexin.

S. aureus bacteremia → TTE/TEE, 2-week minimum IV therapy uncomplicated.

No S. aureus vaccine exists.

HbA1c, HIV testing, fasting glucose in recurrent SSTI workup.

Cephalexin alone does NOT cover MRSA — common distractor.

TMP-SMX does NOT reliably cover group A strep — pair with cephalexin if both coverage needed.

CCS sequence post-I&D: culture → empiric oral abx → 48–72 hr recheck → return precautions.

Board pearl: Mastering the purulent-vs-non-purulent + mild/moderate/severe grid solves ~80% of Step 3 SSTI vignettes.

Board Question Stem Patterns

"A 22-year-old wrestler presents with a tender, fluctuant 3-cm lesion on his thigh that he thinks is a spider bite. Afebrile, vitals normal."

→ I&D with culture + TMP-SMX DS BID × 7 days + 48-hr follow-up + counseling on shared equipment.

"A 55-year-old with diffuse leg erythema, no abscess, no drainage, mild fever, recent tinea pedis."

→ Cephalexin — strep cellulitis; don't add MRSA coverage routinely.

"Patient on cephalexin × 3 days with worsening erythema and new fluctuance."

→ Re-examine, US for abscess, I&D, add TMP-SMX or switch to clindamycin/doxycycline.

"28-year-old at 22 weeks gestation with a forearm abscess."

→ I&D + clindamycin; avoid doxycycline and TMP-SMX.

"78-year-old on warfarin for AF presents with abscess."

→ Use doxycycline or clindamycin to avoid TMP-SMX–warfarin INR spike.

"Patient with pain out of proportion, dusky skin, hemorrhagic bullae, lactate 4."

→ Emergent surgical consult + vancomycin + pip-tazo + clindamycin + admit ICU; do not delay for imaging.

"Third abscess in 5 months, sister had one last month."

→ Decolonization (mupirocin + chlorhexidine), household contact counseling, HbA1c/HIV screening.

"Culture reports clindamycin-susceptible but erythromycin-resistant; patient failing clindamycin."

→ D-test positive — switch agent (TMP-SMX or doxycycline).

"MRSA grows in blood cultures from abscess patient."

→ Vancomycin IV, TTE → TEE if needed, repeat blood cultures q48h until cleared, minimum 2-week therapy, source control.

"5-year-old with recurrent boils, daycare cluster."

→ I&D + clindamycin or TMP-SMX (weight-based), decolonization, counseling.

"Bilateral lower-extremity erythema, hyperpigmentation, weeping, no fever."

→ Stasis dermatitis — compression + topical steroids, not antibiotics.

Stem 1 — Classic CA-MRSA abscess:

Stem 2 — Non-purulent cellulitis:

Stem 3 — Failed beta-lactam:

Stem 4 — Pregnancy:

Stem 5 — Warfarin interaction:

Stem 6 — Necrotizing fasciitis:

Stem 7 — Recurrent abscesses:

Stem 8 — Inducible clindamycin resistance:

Stem 9 — S. aureus bacteremia from SSTI:

Stem 10 — Pediatric:

Stem 11 — Bilateral leg redness:

Board pearl: When the stem gives you fluctuance + purulent + risk factor, the answer is I&D + oral MRSA-active antibiotic + 48-hr follow-up — repeated dozens of times across vignette variations.

One-Line Recap

— Purulent = MRSA; non-purulent = strep. I&D drives outcomes; antibiotics are adjunctive but reduce recurrence and treatment failure for abscesses ≥2 cm or with systemic signs.

— First-line oral agents: TMP-SMX, doxycycline, clindamycin × 5–7 days. Pregnancy → clindamycin. Renal disease → doxycycline or clindamycin (no adjustment). Always culture the pus.

— Always reassess at 48–72 hours. Failure to improve → re-image, broaden coverage, hospitalize. Red flags (pain out of proportion, bullae, crepitus) → emergent surgery + IV vancomycin + pip-tazo + clindamycin.

— Recurrent disease (≥2/6 months) triggers decolonization: intranasal mupirocin BID × 5 days plus chlorhexidine body washes, household contact counseling, hygiene and equipment-sharing education, and screening for diabetes/HIV.

Outpatient MRSA skin and soft tissue infection is managed by incising and draining purulent collections, treating with a short course of an oral MRSA-active antibiotic (TMP-SMX, doxycycline, or clindamycin) when systemic signs, larger lesions, or risk factors are present, reassessing at 48–72 hours, and instituting decolonization plus hygiene measures in recurrent or high-risk cases.

Quick recap bullets:

Board pearl: The Step 3 examiner rewards proceduralism (do the I&D), stewardship (right drug, right duration), follow-up discipline (48–72 hours), and longitudinal thinking (decolonization, comorbidity optimization, transitions of care) — get those four elements right and outpatient MRSA SSTI is reliably a clean win.